Cardiovascular diseases specialist Kiniksa Pharmaceuticals International has announced updates to its pipeline alongside ...

Kiniksa is shifting to next-gen IL-1 antibodies for recurrent pericarditis. Click here to read more on how this impacts KNSA ...

Kiniksa plans to initiate a Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis in mid-2025 - - KPL-387 Phase 1 single ascending dose data support potential monthly dosing - - Kiniksa contin ...

Kiniksa plans to initiate a Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis in mid-2025 –– KPL-387 Phase 1 single ascending dose ...

Q4 2024 and full year 2024 net product revenue of $122.5 million and $417.0 million, respectively –– ARCALYST 2025 net ...

Tarrytown, New York-based Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and ...

Learn more about whether AbbVie Inc. or Regeneron Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor ...

All absentee ballots must be submitted by 5 p.m. on May 20. The district also used the board meeting to celebrate its Regeneron Science Talent Search finalist, Sandeep Sawhney, and to recognize ...

Regeneron Pharmaceuticals, Inc. discovers ... In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes ...

Patients should also avoid live vaccines while taking Arcalyst. Kiniksa paid $5mn to Regeneron (REGN) for this molecule, and has a 50/50 profit sharing arrangement, while bearing all costs.

Regeneron Pharmaceuticals announced positive three-year results from an extension study of EYLEA HD (aflibercept) Injection 8 mg for treating wet age-related macular degeneration (wAMD). The ...